MAIA Biotechnology (MAIA) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed Tenax Therapeutics (TENX) over the past year, losing 36.5% versus a loss of 76.2%. MAIA Biotechnology is the larger company by market cap ($75.3 million vs $69.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | TENX |
|---|---|---|
| Share price | $1.22 | $1.86 |
| Market cap | $75.33M | $69.61M |
| 1-day change | +6.09% | 0.00% |
| YTD return | -24.84% | -84.74% |
| 1-year return | -36.46% | -76.25% |
| 5-year return | — | -99.93% |
| Forward P/E | 1.10 | — |
| EPS (TTM) | $-0.62 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $19.40 |
| 52-week low | $0.87 | $1.31 |
| Distance from 52-week high | -61.76% | -90.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +883.61% | +575.27% |
| Average volume | 527.89K | 5.46M |
| Shares outstanding | 61.74M | 37.42M |
| Employees | 13 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAIA has outperformed TENX by 39.8 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
MAIA vs TENX FAQ
Which is bigger, MAIA Biotechnology or Tenax Therapeutics?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $75.33M compared with $69.61M for Tenax Therapeutics (TENX).
Which stock has performed better over the past year, MAIA or TENX?
MAIA returned -36.46% over the past 12 months, compared with -76.25% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.